Kodak's $765M manufacturing loan on the rocks as red flags multiply

5 Financial Red Flags
Kodak, once famous for its cameras, has been rocked by insider trading allegations in recent days. (Pixabay)

Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows—not only for the size of the loan itself but Kodak's lack of experience. Now, with investigations mounting, the U.S. is pumping the brakes. 

The government put the $765 million loan on hold after "allegations of wrongdoing" on the company's part jeopardized its federally funded move into pharmaceuticals, the U.S. International Development Finance Corporation (DFC) said in a terse tweet Friday. 

Kodak and the DFC signed an interest letter in late July for a loan that would have jumpstarted Kodak's move into manufacturing active pharmaceutical ingredients (API) for a range of  generic drugs.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

The government's interest in Kodak—a photography company that declared bankruptcy in 2012 and has limited experience in drugmaking—as well as insider trading allegations spurred a growing number of investigations in recent days. 

Late last week, a group of influential House Democrats sought documents on the DFC loan, arguing that Kodak didn't appear to have the needed experience to qualify for the massive funding deal. 

RELATED: House Dems launch probe into Kodak's unexpected $765M drug manufacturing loan from the feds

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.